METTL3 and hepatocellular carcinoma: The manipulation of FTO demethylases during the early stages of SARS-CoV-2 infection becomes even more compelling considering the fact that METTL3 knockdown in Huh7 cells can suppress both glycolysis and the mammalian target of rapamycin complex 1 (mTORC1) in patients with hepatocellular carcinoma (HCC) [821], supporting theories that target glucose metabolism and the inhibition of the mTOR pathway as effective treatments for COVID-19 [822,823].